๎
๎ผ
๎
LENZ Therapeutics Inc
LENZ16.890USD
-0.730-4.14%
์ข
๊ฐย 12/23, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
482.86M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ LENZ Therapeutics Inc ํ์ฌ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Companyโs lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ LENZ
ํ์ฌ ์ด๋ฆLENZ Therapeutics Inc
์์ฅ์ผJun 25, 2021
CEOSchimmelpennink (Evert)
์ง์ ์42
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJun 25
์ฃผ์- -
๋์- -
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ- -
์ฐํธ ๋ฒํธ- -
์ ํ- -
์น์ฌ์ดํธ- -
์ข
๋ชฉ ์ฝ๋ LENZ
์์ฅ์ผJun 25, 2021
CEOSchimmelpennink (Evert)
LENZ Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
+1.69%
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
5.39K
+68.95%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
๊ธฐํ
56.13%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
RA Capital Management, LP
13.36%
Alpha Wave Global, LP
11.54%
Versant Ventures
8.49%
Ridgeback Capital Management, L.P.
6.24%
The Vanguard Group, Inc.
4.24%
๊ธฐํ
56.13%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Venture Capital
34.49%
Investment Advisor
26.63%
Hedge Fund
23.81%
Investment Advisor/Hedge Fund
15.67%
Individual Investor
2.52%
Research Firm
2.01%
Pension Fund
0.17%
Bank and Trust
0.13%
Insurance Company
0.02%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Oct 5
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sun, Oct 5
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q3
267
30.95M
100.67%
+981.38K
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
UBS Financial Services, Inc.
881.48K
3.09%
+214.32K
+32.12%
Jun 30, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Tang Capital Management, LLC
897.62K
3.15%
+130.68K
+17.04%
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
State Street SPDR S&P Pharmaceuticals ETF
1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
0.27%
iShares U.S. Pharmaceuticals ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.11%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.06%
๋ ๋ณด๊ธฐ
State Street SPDR S&P Pharmaceuticals ETF
๋น์จ1.18%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
๋น์จ1.04%
Virtus LifeSci Biotech Clinical Trials ETF
๋น์จ0.68%
Invesco Dorsey Wright Healthcare Momentum ETF
๋น์จ0.44%
Invesco Dorsey Wright SmallCap Momentum ETF
๋น์จ0.27%
iShares U.S. Pharmaceuticals ETF
๋น์จ0.22%
ProShares Ultra Nasdaq Biotechnology
๋น์จ0.11%
iShares Micro-Cap ETF
๋น์จ0.09%
Invesco Nasdaq Biotechnology ETF
๋น์จ0.08%
iShares Biotechnology ETF
๋น์จ0.06%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
Mar 19, 2024
Merger
7โ1
Mar 19, 2024
Merger
7โ1
Mar 19, 2024
Merger
7โ1
Mar 19, 2024
Merger
7โ1
๋ ์ง
์ ํ
๋น์จ
Mar 19, 2024
Merger
7โ1
Mar 19, 2024
Merger
7โ1
Mar 19, 2024
Merger
7โ1
Mar 19, 2024
Merger
7โ1
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
LENZ Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎LENZ Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
RA Capital Management, LP๋ 4.18M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 14.65%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Alpha Wave Global, LP๋ 3.61M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 12.66%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Versant Ventures๋ 2.88M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 10.10%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Ridgeback Capital Management, L.P.๋ 1.95M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.84%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 1.29M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 4.52%๋ฅผ ์ฐจ์งํฉ๋๋ค.
RA Capital Management, LP๋ 4.18M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 14.65%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Alpha Wave Global, LP๋ 3.61M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 12.66%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Versant Ventures๋ 2.88M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 10.10%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Ridgeback Capital Management, L.P.๋ 1.95M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.84%๋ฅผ ์ฐจ์งํฉ๋๋ค.
The Vanguard Group, Inc.๋ 1.29M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 4.52%๋ฅผ ์ฐจ์งํฉ๋๋ค.
LENZ Therapeutics Inc์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎LENZ Therapeutics Inc์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures์ ๋๋ค.
RA Capital Management, LP
Alpha Wave Global, LP
Versant Ventures์ ๋๋ค.
LENZ Therapeutics Inc(LENZ)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q3 ๊ธฐ์ค์ผ๋ก, LENZ Therapeutics Inc์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 267๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 30.95M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 100.67%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q2 ๋๋น -3.78% ์ฆ๊ฐํ ์์น์
๋๋ค.
LENZ Therapeutics Inc์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎-- ๊ธฐ์ค, LENZ Therapeutics Inc์ -- ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ --๋ก ์ ์ฒด ๋งค์ถ์ --%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
